Synonyms: CVT-303 | Ranexa® | RS-43285 | RS-43285-003
ranolazine is an approved drug (FDA (2006), EMA (2008))
Compound class:
Synthetic organic
Comment: The mechanism of action of ranolazine is largely unknown, but may have some antianginal effects by inhibition of the late sodium current in cardiac cells.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: ranolazine |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
The precise mechanism by which this drug works is unknown. However, ChEMBL lists the sodium channel type IV and V alpha subunits (SCN4A and SCN5A respectively) as the molecular targets of this drug. These proteins mediate voltage-dependent sodium ion permeability of excitable membranes [1]. SCN4A is also known as the skeletal muscle sodium channel isoform and SCN5A is known as the cardiac sodium channel isoform. So SCN5A is potentially responsible for the drug's cardiac effects. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |